Evidence map›Paper›PMID 38764351›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2025

Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System (SNDS).

A Havet, C Bouvard, A Moskal, M Chanelière, J Massardier, B Lebrun-Vignes, A-P Jonville-Bera, C Payet, M Viprey

Abstract read
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A HavetResearch on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.ORCID https://orcid.org/0000-0002-5474-2064
C BouvardResearch on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.ORCID https://orcid.org/0009-0004-3825-5284
A MoskalResearch on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.ORCID https://orcid.org/0000-0003-4127-4334
M ChanelièreResearch on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.
J MassardierService de Gynécologie-Obstétrique, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Lyon, France.
B Lebrun-VignesService de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Pitié-Salpêtrière, AP-HP, GH Sorbonne Université, Paris, France.ORCID https://orcid.org/0000-0001-6676-5063
A-P Jonville-BeraCentre Régional de Pharmacovigilance, CHRU de Tours, Hôpital Bretonneau, Tours, France.ORCID https://orcid.org/0000-0002-2635-3360
C PayetResearch on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.
M VipreyResearch on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.ORCID https://orcid.org/0000-0002-3281-1970

Funding

Agence Nationale de Sécurité du Médicament et des Produits de Santé 2021S011
6 · The paper itself

Abstract

backgroundDespite the French pregnancy prevention program (PPP), a considerable number of pregnancies are potentially exposed to oral isotretinoin. New measures were taken by the French Medicines Agency, including the restriction of initial isotretinoin prescriptions to dermatology specialists in May 2015 and a new information campaign on teratogenicity in January 2019.

objectivesThe aims were to: describe, between 2014 and 2021, compliance with PPP recommendations: isotretinoin use as a second-line treatment, first prescription by a dermatology specialist, monthly prescription renewal and pregnancy testing (PT); assess the effect of the 2015 and 2019 measures on PT compliance; and identify the determinants of PT noncompliance.

methodsA retrospective cohort study was conducted among women aged 11-50 years initiating isotretinoin between 2014 and 2021 using the French Health Data System. PT compliance corresponded to pregnancy test completion and specific delays between prescription and dispensation. Time series analyses were performed to evaluate the effect of the 2015 and 2019 measures on PT compliance, and log-binomial and Poisson multivariate regression models were used to identify the determinants of PT noncompliance.

resultsIsotretinoin was prescribed as a second-line treatment in 64% of initiations, mainly by dermatology specialists (92%). A new monthly prescription was observed in 98% of dispensations. PT compliance reached 61%, 72% and 25% at initiation, renewals and end of treatment, respectively. The 2015 measure was associated with better PT compliance at initiation and renewals. The 2019 measure had no significant effect on PT compliance at the initiation or end of treatment but was associated with a decrease in PT compliance at renewals. Age, low socioeconomic level, initiation by a nondermatology specialist and during summer were associated with PT noncompliance.

conclusionsUnderstanding factors associated with PT noncompliance could help to target specific subpopulations of women treated with isotretinoin.

Indexed as

Acne VulgarisDermatologic AgentsIsotretinoinPatient ComplianceAdolescentAdultChildCohort StudiesFemaleFranceHumansMiddle AgedPregnancyRetrospective StudiesYoung AdultDermatologic AgentsIsotretinoin

Identifiers

PMID38764351
PMCPMC11934010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.